Bayer: new indication for Nubeqa in China

(CercleFinance.com) - Bayer announced on Tuesday that the Chinese Medicines Agency has approved Nubeqa in combination with docetaxel for the treatment of hormone-sensitive metastatic prostate cancer (mHSPC).


The German pharma company says that Nubeqa, which it markets with Finnish company Orion, was already approved in China for the treatment of patients with castration-resistant and non-metastatic prostate cancer (mHSPC), but who had a high risk of developing metastases.

The approval comes at a time when prostate cancer cases have increased significantly in China in recent years, with nearly one in three patients now diagnosed with metastatic disease.

In clinical trials, Nubeqa in combination with docetaxel reduced the risk of death in patients with mHSPC by 32.5% compared to ADT plus docetaxel.


Copyright (c) 2023 CercleFinance.com. All rights reserved.